Sangamo Therapeutics to Release First Quarter 2025 Financial Results and Host Earnings Conference Call on May 12
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company developing transformative therapies using its proprietary platform technologies, announced today that it will release its financial results for the first quarter ended March 31, 2025, after the market closes on Monday, May 12, 2025.
Following the release, Sangamo will host a public conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) the same day. Company executives will review the financial performance for the quarter, provide corporate and pipeline updates, and discuss strategic priorities for the rest of 2025.
The conference call is open to all interested parties. To participate, attendees are encouraged to register in advance via the link provided by the company. Upon registration, participants will receive instructions for joining the call, including a dial-in number and a unique passcode. Alternatively, users may select the dial-out option, which enables the system to call their phone directly. For the best experience and to avoid delays, Sangamo recommends logging in or dialing in approximately 10 minutes before the scheduled start time.
In addition to the teleconference, a live audio webcast of the earnings call will be accessible on the Sangamo Therapeutics website, specifically in the Investors and Media section under “Events.” A replay of the webcast will also be made available for those unable to attend the live session.
About Sangamo Therapeutics
Headquartered in Brisbane, California, Sangamo Therapeutics is at the forefront of genomic medicine. The company is focused on developing gene therapy, gene editing, and cell therapy-based treatments for serious and life-threatening genetic diseases. Utilizing its proprietary zinc finger protein (ZFP) technology platform, Sangamo has built a diverse pipeline aimed at addressing a range of conditions, including neurodegenerative disorders, hemophilia, lysosomal storage diseases, and sickle cell disease.
Sangamo’s platform includes both in vivo and ex vivo approaches to genome engineering. Its ZFP transcription factors and nucleases enable the company to regulate or modify genes with high precision. Over the past several years, Sangamo has forged multiple strategic collaborations with leading pharmaceutical companies, including Biogen, Novartis, Sanofi, and Pfizer, to accelerate development and commercialization efforts.
The company’s portfolio includes several preclinical and clinical-stage programs, and quarterly earnings calls such as the one scheduled for May 12 provide investors, analysts, and stakeholders with critical insight into both recent progress and long-term goals.
What to Expect from the Q1 2025 Earnings Call
While Sangamo has not yet disclosed preliminary results, investors will be closely watching for updates on a few key areas:
- Financial Performance
The earnings release will include a detailed review of the company’s financial position as of March 31, 2025. This typically includes revenue, research and development expenses, general and administrative costs, net income or loss, cash runway, and operational metrics. As a clinical-stage biotech company, Sangamo’s financial health is closely monitored to ensure that sufficient capital is available to fund research and development programs. - Pipeline Updates
Investors will likely hear updates on Sangamo’s ongoing and planned clinical trials. Particular attention may be given to:- Progress on the ST-920 gene therapy program for Fabry disease
- Clinical timelines and data expectations for TX200, the company’s CAR-Treg cell therapy
- Updates on collaborative programs with Pfizer (hemophilia A) and Novartis (neurodevelopmental disorders)
- Early-stage research in areas such as neurological diseases and oncology
- Strategic Developments and Collaborations
Investors may receive updates on strategic partnerships, licensing agreements, or changes to collaboration terms. Sangamo’s ability to attract and maintain partnerships with major pharmaceutical firms serves as validation of its underlying science and platform potential. - Regulatory and Operational Milestones
Sangamo might provide insights into upcoming regulatory interactions, including Investigational New Drug (IND) submissions, feedback from the U.S. Food and Drug Administration (FDA) or international regulators, and timelines for potential pivotal trials or commercial launches. - Corporate Strategy and Outlook
With the biotech industry continuing to face macroeconomic pressures, management commentary on Sangamo’s cost control initiatives, prioritization of key programs, and capital allocation strategies will be of high interest. The company’s efforts to streamline operations or shift resources toward higher-priority programs may be discussed.
Importance of Earnings Calls for Biotech Investors
Earnings calls play a pivotal role in investor communication for biotech firms like Sangamo Therapeutics. Unlike more mature industries that rely on steady revenues and product sales, early-stage biotech firms often report limited revenue but are valued based on their scientific progress, clinical development timelines, and potential future market opportunity.
As such, these calls are not solely about financial numbers—they’re strategic communication events that provide transparency into how a company is navigating its scientific, regulatory, and business challenges. Analysts often use the information shared during earnings calls to update their financial models, revise their price targets, or reassess the company’s long-term investment thesis.
How to Join the Earnings Call
Participants who wish to listen to Sangamo’s Q1 2025 earnings call can do so through the registration link provided by the company. While the link is not included in this release, it is accessible on Sangamo’s website under the Investors and Media > Events section. Once registered, participants may choose to join by phone (with the provided dial-in information and passcode) or opt for the convenience of a direct dial-out, where the system calls their phone at the appointed time.
The live webcast, which is recommended for those preferring to follow along via computer or mobile device, will stream simultaneously with the audio call. A replay of the event, including an audio archive and possibly a transcript, will be made available shortly after the call concludes.
As with all corporate announcements, the upcoming earnings call may contain forward-looking statements related to Sangamo’s plans, strategies, and anticipated developments. These statements are subject to risks and uncertainties, and actual outcomes may differ from what is discussed. Listeners are encouraged to review Sangamo’s filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Form 10-K and Form 10-Q, for a full overview of risk factors and disclosures.
Sangamo Therapeutics, Inc. is a genomic medicine company committed to translating ground-breaking science into genomic therapies that transform patients’ lives. The company is developing product candidates across three key areas: gene therapy, cell therapy, and genome editing. Founded in 1995 and headquartered in Brisbane, California, Sangamo is a pioneer in zinc finger protein technology and continues to advance innovation through its integrated platform.
